Allergan Says Valeant Valuation Of New Eye Drug Falls Short
A much-anticipated Allergan Inc. eye treatment that could add another $25 per share to a $53 billion buyout offer from Valeant Pharmaceuticals International Inc. moved to the next stage of the...To view the full article, register now.
Already a subscriber? Click here to view full article